Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Acquired by WealthBridge Investment Counsel Inc.

WealthBridge Investment Counsel Inc. increased its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.4% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 11,487 shares of the medical research company’s stock after buying an additional 265 shares during the quarter. Thermo Fisher Scientific comprises approximately 2.1% of WealthBridge Investment Counsel Inc.’s investment portfolio, making the stock its 25th biggest holding. WealthBridge Investment Counsel Inc.’s holdings in Thermo Fisher Scientific were worth $5,716,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Bernard Wealth Management Corp. purchased a new stake in shares of Thermo Fisher Scientific during the fourth quarter valued at $25,000. Barrett & Company Inc. purchased a new stake in shares of Thermo Fisher Scientific during the fourth quarter valued at $28,000. FPC Investment Advisory Inc. purchased a new stake in shares of Thermo Fisher Scientific during the fourth quarter valued at $28,000. Pillar Financial Advisors LLC purchased a new stake in shares of Thermo Fisher Scientific during the fourth quarter valued at $29,000. Finally, Ameriflex Group Inc. purchased a new stake in shares of Thermo Fisher Scientific during the fourth quarter valued at $30,000. 89.23% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on TMO shares. The Goldman Sachs Group set a $610.00 price objective on shares of Thermo Fisher Scientific and gave the company a “buy” rating in a report on Wednesday, April 23rd. Barclays cut their price target on Thermo Fisher Scientific from $620.00 to $475.00 and set an “equal weight” rating on the stock in a research report on Thursday, April 10th. Royal Bank of Canada cut their price target on Thermo Fisher Scientific from $651.00 to $637.00 and set an “outperform” rating on the stock in a research report on Thursday, April 24th. Citigroup cut their price target on Thermo Fisher Scientific from $650.00 to $570.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 4th. Finally, UBS Group cut their price target on Thermo Fisher Scientific from $715.00 to $500.00 and set a “buy” rating on the stock in a research report on Thursday, April 24th. Four equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $605.30.

Thermo Fisher Scientific Trading Up 0.9%

TMO stock opened at $401.99 on Friday. The company’s 50-day simple moving average is $420.74 and its 200-day simple moving average is $495.93. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59. Thermo Fisher Scientific Inc. has a 52-week low of $390.50 and a 52-week high of $627.88. The firm has a market cap of $151.75 billion, a P/E ratio of 24.32, a PEG ratio of 2.99 and a beta of 0.78.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.10 by $0.05. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. The business had revenue of $10.36 billion for the quarter, compared to analyst estimates of $10.23 billion. During the same period in the prior year, the company posted $5.11 EPS. The company’s revenue for the quarter was up .2% on a year-over-year basis. As a group, equities analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, July 15th. Investors of record on Friday, June 13th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 0.43%. The ex-dividend date is Friday, June 13th. Thermo Fisher Scientific’s dividend payout ratio is presently 10.09%.

Insider Activity at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 300 shares of the firm’s stock in a transaction dated Monday, April 28th. The shares were sold at an average price of $429.93, for a total value of $128,979.00. Following the transaction, the executive vice president now directly owns 23,167 shares of the company’s stock, valued at approximately $9,960,188.31. This trade represents a 1.28% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Michael A. Boxer sold 3,775 shares of the firm’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the completion of the transaction, the senior vice president now directly owns 10,816 shares in the company, valued at $5,759,736.32. This represents a 25.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.33% of the stock is currently owned by corporate insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.